

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 23 MAY 2025

References are made to the notice of extraordinary general meeting (the “**EGM Notice**”) and circular (the “**Circular**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) both dated 2 May 2025. Capitalised terms used in this announcement shall have the same meanings as those defined in the Circular, unless otherwise specified herein.

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that at the Extraordinary General Meeting held on 23 May 2025, all the ordinary resolutions (“**Ordinary Resolutions**”) and a special resolution (“**Special Resolution**”, together with the Ordinary Resolutions, referred to as, the “**Resolutions**”) as set out in the EGM Notice were duly passed by the Shareholders by way of poll. The poll results in respect of the Resolutions passed at the Extraordinary General Meeting were as follows:

ORDINARY RESOLUTIONS		No. of votes cast and percentage of total number of votes cast	
		For	Against
1.	To consider and approve the proposed by-election of Independent Non-Executive Director.	289,028,378 (98.2510%)	5,144,987 (1.7490%)
2.	To consider and approve the proposed by-election of Non-Executive Director.	287,988,682 (97.8976%)	6,184,683 (2.1024%)
3.	To consider and approve the proposed application for Full Circulation of unlisted shares of the Company.	280,762,766 (95.4413%)	13,410,599 (4.5587%)

ORDINARY RESOLUTIONS		No. of votes cast and percentage of total number of votes cast	
		For	Against
4.	To consider and approve the proposed grant of authorization to the Board of Directors and its delegated persons to handle matters related to the application for Full Circulation of unlisted shares of the Company.	280,762,766 (95.4413%)	13,410,599 (4.5587%)
5.	To consider and approve the proposed appointment of new auditors: (i) appoint Daxin Global (Hong Kong) Certified Public Accountants Ltd. as the new auditor of the Company; (ii) the auditors' fee for the new auditor shall be RMB1.65 million; and (iii) authorise the Directors to execute all such documents, instruments and agreements and do all such acts or things to give effect to the above appointment of new auditors and matters connected therewith.	287,988,682 (97.8976%)	6,184,683 (2.1024%)
SPECIAL RESOLUTION		No. of votes cast and percentage of total number of votes cast	
		For	Against
6.	To consider and approve the proposed amendments to the Articles of Association.	279,450,070 (95.0833%)	14,450,295 (4.9167%)

As more than 50% of the votes were cast in favour of each of the Ordinary Resolutions numbered 1 to 5 above, the Ordinary Resolutions numbered 1 to 5 above were duly passed as Ordinary Resolutions of the Company. As not less than two-third of the votes were cast in favour of the Special Resolution, the Special Resolution was duly passed as a Special Resolution of the Company.

As at the date of the Extraordinary General Meeting, the total number of issued Shares was 364,588,000 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions at the Extraordinary General Meeting. There were no Shares entitling the holders to attend and abstain from voting in favour of the any resolutions at the Extraordinary General Meeting as set out in Rule 13.40 of the Listing Rules. No other Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions at the Extraordinary General Meeting. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the above resolutions.

All Directors of the Company, namely Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng, Dr. Guan Jin, Mr. Tang Jin, Mr. Zhu Pai and Dr. Meng Songdong, attended the Extraordinary General Meeting either in person or by electronic means.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer at the Extraordinary General Meeting for the vote-taking.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Hong Kong, 23 May 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Manfred Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.